|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although potent androgen receptor pathway inhibitors (ARPI) improve overall survival of metastatic prostate cancer patients, treatment-induced neuroendocrine prostate cancer (t-NEPC) as a consequence of the selection pressures of ARPI is becoming a more common clinical issue.
|
28427194 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present findings showing frequent expression of structurally unaltered androgen receptor in an advanced stage of EMPD may provide a rational basis for hormone therapy, which is widely used in the treatment of metastatic prostate cancer and androgen receptor-positive breast cancer recurrence.
|
11005214 |
2000 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The standard treatment for metastatic prostate cancer, androgen deprivation therapy (ADT), is designed to suppress androgen receptor (AR) activity.
|
30242112 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vitro reporter assays revealed that the hON-522E promoter is highly active in androgen receptor negative and metastatic prostate cancer and bone stromal cells compared to androgen receptor-positive prostate cancer cells.
|
27054343 |
2016 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent genomic analyses of metastatic prostate cancer have provided important insight into adaptive changes in androgen receptor (AR) signaling that underpin resistance to androgen deprivation therapies.
|
29530945 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study also highlights that approaches to target advanced PC require intelligent combination of agents to target single/multiple signalling pathways in combination with androgen receptor (AR) blockade.
|
29314004 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We showed that AR, MMP-9 and EGFR are interconnect factors, which may cooperatively promote PCa progression.
|
30134822 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article, we discuss the current knowledge of mechanisms via which the AR signaling drives therapeutic resistance in prostate cancer metastatic progression and the novel therapeutic interventions targeting AR in CRPC.
|
24948871 |
2014 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we highlight recent progress and ongoing trials for metastatic prostate cancer, including advances in chemotherapy, androgen receptor-directed therapy, targeted therapies, and immunotherapy.
|
29644451 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results from the present study suggest that 3α-diol may act as an alternative intra-prostatic neurosteroid that activates AR-independent PCa progression.
|
29155210 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Selectivity in coregulator-dependent AR action is reflected in differential AR binding site composition and involvement with CaP biology and progression.
|
28826481 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inactivation of the androgen receptor (AR) pathway by androgen deprivation therapy (ADT) is the mainstay of (metastatic) prostate cancer therapy.
|
29276148 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL8 Expression Is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer.
|
31604846 |
2020 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Then the development, the performance evaluation and contextualization in a clinical setting of this standardized operating procedure (SOP) have been reported to evaluate the prognostic biomarker AR-V7 in metastatic prostate cancer.
|
30141201 |
2019 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings highlight an association between GSK-3/AR and NFκB signaling and its potential clinical importance in metastatic prostate cancer.
|
25327559 |
2014 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen ablation is the primary treatment modality for patients with metastatic prostate cancer; however, the role of androgen receptor signaling in prostate cancer development remains enigmatic.
|
15604246 |
2004 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate cancer is an androgen-dependent disease; metastatic prostate cancer is typically treated by androgen receptor (AR) blockade.
|
17079484 |
2006 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antiandrogens have a peculiar place in the treatment of metastatic prostate cancer by blocking the androgen receptor (AR).
|
30831197 |
2019 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, the 20q13 region was shown to be frequently co-amplified with the androgen receptor (AR) in metastatic prostate cancer.
|
24379448 |
2014 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate cancer progression is controlled by the androgen receptor and new blood vessel formation, or angiogenesis, which promotes metastatic prostate cancer growth.
|
28394264 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibiting androgen receptor (AR) signaling with androgen deprivation therapy (ADT) represents the mainstay of therapy for advanced and metastatic prostate cancer.
|
30396917 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibiting the androgen receptor (AR) pathway is an important clinical strategy in metastatic prostate cancer.
|
28219796 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Du145 and PC3, two cell lines from advanced metastatic prostate cancer, which are characterized as androgen-independent and -insensitive, did not express AR but expressed a high level of WT1.
|
11299720 |
2001 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer.
|
19257827 |
2009 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we found that there was a significant correlation between MMP9 and AR protein expression in primary and metastatic PCa tissues, and a trend that high level of MMP9 expression was associated with poor prognosis.
|
31381135 |
2020 |